Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty.

摘要

In children, CML is rare, imatinib is well tolerated, and molecular remission can be achieved. However, up until now, no information on the growth of children taking imatinib has been reported. The mechanism of transient growth deceleration in this case is uncertain. The patient had no history of medication that could interfere with growth, he had normal body proportions and appearance, no hypothyroidism, was not undernourished, had normal serum values of insulin-like growth factor 1, a radiograph of the left hand at 15 years showed a corresponding bone age, and the growth velocity eventually recovered. The timing of growth deceleration in relation to the start of imatinib administration suggests a possible causal relation. However, in the absence of provocative testing for growth hormone, random measurements are inconclusive, and atransient growth hormone deficiency cannot be excluded.